Health Condition 1: null- Type II Diabetic
Conditions
Interventions
Intervention1: Dapagliflozen 10 mg Once Daily: SGLT2 inhibitor and duration of the action of the drug is 24 hrs. total duration of study is 3 years
Control Intervention1: Vildagliptin 50mg Once Daily:
Sponsors
siddhartha medical college
Eligibility
Inclusion criteria
Inclusion criteria: Males and Females of age between 30-60 years Type â?? 2 diabetics already on treatment but with uncontrolled blood sugars. Type â?? 2 diabetics with hypertension. Type â?? 2 diabetics with obesity
Exclusion criteria
Exclusion criteria: Males and Females of age above 60 years . Newly diagnosed cases of Type â?? 2. Type â?? 2 diabetics with other endocrinological disorders like hypo or hyperthyroidism, cushingâ??s syndrome and acromegaly, Type â?? 2 diabetics with pancreatic disorders like pancreatitis. , Type â?? 2 Diabetics with acute complications. Type â?? 2 Diabetics on drugs like thiazide diuretics, corticosteroids, oral contraceptive pills, protease inhibitors. Other specific types of diabetes like MODY. Type â?? 2 Diabetics with severe renal failure, heart failure, and hepatic failure. Pregnant & lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Glycemic reduction (HbA1c) by glucose lowering effect of dapagliflozen 10 mg OD vsvildagliptin 50 mg OD when added to metformin and glimepride groupTimepoint: 1 year | — |
Secondary
| Measure | Time frame |
|---|---|
| reduction of macro and micro vascular complicationsTimepoint: 2 years | — |
Countries
India
Contacts
Public ContactDr Kurli Sankar
Siddhartha Medical College
Outcome results
None listed